Oct4 and Bmi1 Reprogramming for Pluripotent Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPS cells) require multiple gene factors, which complicates the understanding of molecular mechanisms and practical clinical use, and existing stem cell therapies face challenges such as ethical issues with embryonic stem cells and immunological rejection.
Innovation Solution
The use of Oct4 in combination with Bmi1 or its upstream regulator, such as Shh or its analogs, to reprogram somatic cells into embryonic stem cell-like cells, reducing the number of genes needed and overcoming ethical and immunological challenges.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple gene factors are used to generate induced pluripotent stem cells, then reprogramming efficiency is improved, but device complexity and difficulty of understanding molecular mechanisms increase
Solution Approach 1:
The patent extracts and identifies the essential core factors required for reprogramming by testing combinations of gene factors. It determines that Oct4 combined with Bmi1 or its upstream regulators (Shh, oxysterol, purmorphamine) is sufficient for reprogramming, eliminating the need for multiple traditional factors (Sox2, Klf4, c-Myc) and simplifying the system while maintaining reprogramming efficiency.
2Adaptability or versatility
If embryonic stem cells are used for therapy, then differentiation potential is improved, but ethical issues and immunological rejection occur
Solution Approach 1:
The patent creates induced pluripotent stem cells that copy the essential properties of embryonic stem cells through reprogramming somatic cells. These iPS cells exhibit similar differentiation potential and self-renewal capabilities while being derived from the patient's own somatic cells, thereby avoiding ethical issues associated with embryonic stem cell destruction and reducing immunological rejection risks.
3Object-affected harmful factors
If adult stem cells are used for therapy, then immunological rejection is reduced, but differentiation potential and self-renewal capacity are limited
Solution Approach 1:
The patent changes the state of somatic cells by introducing reprogramming factors (Oct4 and Bmi1 or its regulators) that alter gene expression patterns and epigenetic marks. This transforms differentiated somatic cells into pluripotent iPS cells, fundamentally changing their differentiation potential and self-renewal capacity while maintaining their patient-specific identity to avoid immunological rejection.
Data Source
AI summary
Disclosed is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule coding for Bmi1; and b) an Oct4 protein or a nucleic acid molecule coding for Oct4. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the genetic factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.